Best Peptides for Muscle Growth: What the Community Actually Uses (2026)

The peptides most used for muscle growth are the growth-hormone secretagogues - the CJC-1295+ipamorelin stack leads by a wide margin, followed by oral MK-677 - with the direct anabolic IGF-1 LR3 in third, but "most used" is not the same as "best for you," and not one of them is FDA-approved for building muscle in a healthy adult. This page answers the real question two ways at once: what the ProtocolPlus community reaches for, and what the evidence honestly says about each option.

Most "best peptides for muscle growth" lists do one of two things, and neither helps you choose. They re-explain CJC-1295's half-life for the tenth time, or they pile every growth peptide into one undifferentiated heap. We do it differently. The headline ranking below comes from first-party usage data - what ~3,000 ProtocolPlus users pursuing muscle growth actually track - and we organize the editorial "why" around the single distinction that actually decides this category: whether a compound works indirectly, by raising your own growth hormone, or directly, by acting on muscle and IGF signaling itself. For the deep science, mechanism, and dosing on any single compound, we link up to its dedicated guide so this page stays a clean decision hub.

Key Takeaways

• What the community uses (not an efficacy ranking): across ~3,000 ProtocolPlus users pursuing muscle growth, the top three are the CJC-1295+ipamorelin stack (28%), oral MK-677 (16%), and the direct IGF-1 LR3 (14%), with sermorelin (10%), tesamorelin (8%), MGF (6%), BPC-157 as recovery support (5%), follistatin-344 (5%), hexarelin (4%), and an "other" tail (4%) behind (ProtocolPlus app data).
• The one distinction that decides everything: indirect vs direct. Indirect GH-axis secretagogues (CJC/ipa, MK-677, sermorelin, tesamorelin, hexarelin) raise your own growth hormone. Direct anabolics (IGF-1 LR3, MGF, follistatin-344) act on muscle/IGF signaling itself - a stronger, more direct signal, but with the least human evidence and the most safety uncertainty.
• No peptide here is FDA-approved for muscle growth in healthy adults. Tesamorelin is approved, but for HIV-associated visceral fat, not lean mass. Everything else is investigational or research-grade, and all of it is banned in tested sport (WADA).
• The honest evidence picture: the GH secretagogues at least have human GH/IGF-1 data (and MK-677 and tesamorelin have real human trials), while the direct anabolics - especially follistatin-344 - rest on animal data with the biggest gap between hype and human proof.
• The glucose caveat is real and concrete. MK-677 and IGF-1 LR3 can raise fasting glucose and blunt insulin sensitivity; our observed bloodwork data below makes this visible. If you use either, fasting-glucose and IGF-1 monitoring is the price of entry.
• New to this? Start indirect. The beginner-safe pick the community reaches for is the single canonical CJC-1295+ipamorelin stack (or milder sermorelin), not the direct IGF/myostatin compounds.
• Want indirect-only or low-monitoring? Filter the selector above: the mechanism filter splits the field into GH-axis vs direct anabolic, and the monitoring filter de-prioritizes MK-677 and IGF-1 LR3.

What peptides does the ProtocolPlus community use for muscle growth?

Across ~3,000 ProtocolPlus users pursuing muscle growth, the CJC-1295+ipamorelin GH-axis stack is the most-tracked option by a wide margin (28%), followed by oral MK-677 (16%) and the direct IGF-1 LR3 (14%) - so the top three account for nearly six in ten users. This is a usage ranking from our own app data, not a clinical verdict on what works best.

The pattern tells you almost everything about how this community thinks. The top of the list is dominated by indirect GH-axis secretagogues: the canonical CJC-1295+ipamorelin combination at 28%, oral MK-677 at 16%, sermorelin at 10%, and tesamorelin at 8% together make the GH-axis approach the clear default. People reach for it first because it works with the body's own growth-hormone system rather than overriding it, and because the CJC/ipa stack has become the genre's "starter pack." Only one direct anabolic breaks into the top tier: IGF-1 LR3 at 14%, used by the more experienced cohort chasing a stronger signal.

After the leaders, usage drops into a tail that mixes mechanisms: MGF (6%), a local IGF splice variant; BPC-157 (5%), which is not a muscle-builder at all but a recovery adjunct people stack to stay trainable; follistatin-344 (5%), the most-hyped myostatin-inhibitor concept with the least human proof; hexarelin (4%), an older, more aggressive GHRP; and a 4% "other" bucket holding IGF-1 DES and the older GHRPs (GHRP-2 and GHRP-6). These shares come only from our community-usage dataset and describe behavior, not efficacy. A compound can be widely used and weakly evidenced at the same time - follistatin-344 is exactly that case, with an outsized reputation and zero human muscle trials.

Citation capsule. Among ~3,000 ProtocolPlus users who logged muscle growth as a goal, the most-tracked options were the CJC-1295+ipamorelin stack (28%, 840 users), MK-677 (16%, 480), and IGF-1 LR3 (14%, 420), followed by sermorelin (10%, 300), tesamorelin (8%, 240), MGF (6%, 180), BPC-157 as recovery support (5%, 150), follistatin-344 (5%, 150), hexarelin (4%, 120), and an "other" tail (4%, 120). This is first-party usage data reflecting what the community uses, not a clinical efficacy ranking. Source: ProtocolPlus app data (goals/muscle-growth.json), 2026.

The community's top 3 picks (by usage)

The community's three most-used muscle-growth peptides are the CJC-1295+ipamorelin stack, MK-677, and IGF-1 LR3 - two indirect GH-axis secretagogues and one direct IGF-1 analog. Each card below pairs the usage share with the honest reason people pick it and the caveat that comes with it.

These three account for roughly 58% of muscle-growth usage in our cohort. The split tracks a simple logic: most people start with the GH-axis approach because it works with the body's own hormone system and the CJC/ipa stack is the genre's default starter, then a more experienced minority graduates to a direct IGF signal. Notice that the two leaders are indirect and the only direct compound in the top three sits in third - a preview of the page's central distinction.

The long tail (ranks 4-10): the remaining ~42% of usage spreads across sermorelin (10%), tesamorelin (8%), MGF (6%), BPC-157 as recovery support (5%), follistatin-344 (5%), hexarelin (4%), and an "other" bucket (4%). Sermorelin and tesamorelin are gentler and better-evidenced GH-axis options (tesamorelin is actually FDA-approved, but for visceral fat, not muscle); MGF and follistatin-344 are direct anabolics with animal data only; BPC-157 is a recovery adjunct rather than a muscle-builder; hexarelin is an older, more aggressive GHRP; and "other" gathers IGF-1 DES and the legacy GHRPs (GHRP-2 and GHRP-6). Each gets a mini-section below.

How do muscle-growth peptides actually work?

Muscle-growth peptides split cleanly into two mechanisms, and that split is the single most useful thing to understand on this page: indirect GH-axis secretagogues raise your own growth hormone and IGF-1, while direct anabolics act on muscle and IGF signaling itself. The indirect route is gentler and works with your physiology; the direct route is a stronger, more aggressive signal with far less human safety data.

The indirect group is by far the larger camp, and it has two sub-types that the community usually pairs. GHRH analogs (CJC-1295, sermorelin, tesamorelin) mimic growth-hormone-releasing hormone and tell the pituitary to release more of its own GH. GH-releasing peptides, or GHRPs (ipamorelin, hexarelin, and the oral ghrelin-mimetic MK-677), act on the ghrelin receptor to trigger a separate GH pulse. Combining a GHRH analog with a GHRP - the CJC-1295+ipamorelin stack is the textbook example - produces a larger, more synergistic GH release than either alone, which is exactly why that stack tops the usage chart. The key honesty: all of these raise GH and IGF-1, and higher IGF-1 supports muscle protein synthesis, but raising your own GH is not the same as a proven muscle-building drug, and none has a human muscle-growth trial in healthy adults.

The direct group skips the GH axis entirely and is where the science gets both more interesting and more speculative. IGF-1 LR3 is a long-acting IGF-1 analog that binds IGF-1 receptors on muscle directly. MGF (mechano-growth factor) is a splice variant of IGF-1 the body produces locally after mechanical loading, studied for activating muscle satellite cells. And follistatin-344 works by a different logic again: instead of pushing growth, it inhibits myostatin, the natural "brake" that limits how much muscle you can build - the mechanism behind those striking "double-muscled" cattle. On paper, removing the brake or amplifying the local growth signal sounds more powerful than nudging the GH axis. In practice, these direct compounds have animal and preclinical data only for muscle, carry the most safety uncertainty, and have the biggest gap between hype and human proof. The receptor-level science for any single compound lives on its hub; for the foundations of how peptides act in the body, see how peptides work.

Citation capsule. Muscle-growth peptides act through two mechanisms. Indirect GH-axis secretagogues raise the body's own growth hormone and IGF-1: GHRH analogs (CJC-1295, sermorelin, tesamorelin) plus GH-releasing peptides (ipamorelin, hexarelin, oral MK-677), often paired for synergy. Direct anabolics act on muscle and IGF signaling itself: IGF-1 LR3 (a long-acting IGF-1 analog), MGF (a local IGF splice variant), and follistatin-344 (a myostatin inhibitor). No peptide in either group is FDA-approved for muscle growth in healthy adults. Source: GH-secretagogue and IGF-1/myostatin pharmacology literature, plus MK-677 and tesamorelin human trials.

Indirect or direct? The decision that defines the category

The most useful way to choose is by mechanism tier: indirect GH-axis secretagogues (CJC/ipa, MK-677, sermorelin, tesamorelin, hexarelin) are the gentler, better-evidenced, beginner-appropriate default, while direct anabolics (IGF-1 LR3, MGF, follistatin-344) are a stronger, more direct signal that the experienced minority accepts despite less human data and more risk. This mechanism split is the signature of this page, and it is editorial context, not the usage headline.

This is the bridge most muscle-peptide content never builds. The GH-axis crowd treats CJC/ipa as the whole conversation; the direct-anabolic crowd talks about IGF-1 LR3 and follistatin as if the GH approach does not exist. The chart below puts both tiers on one grid so you can see the trade explicitly: as you move from indirect to direct, the potential signal gets more aggressive, but the human evidence thins and the safety uncertainty grows.

The decision table below puts the same logic in detail, adding route, evidence, monitoring burden, and the "picked when" trigger for each candidate. The selector quiz at the top runs this interactively: choosing indirect surfaces the GH-axis secretagogues, choosing direct surfaces IGF-1 LR3, MGF, and follistatin-344, and the monitoring filter de-prioritizes the two compounds (MK-677, IGF-1 LR3) that most warrant glucose tracking.

How strong is the evidence, really, for each one?

On muscle-growth-specific human evidence, the honest ladder is short and uncomfortable: no peptide here has a controlled trial showing it builds muscle in healthy adults, the indirect GH secretagogues at least have human GH/IGF-1 trial data (MK-677 and tesamorelin most of all), and the direct anabolics - especially follistatin-344 - rest on animal data with the biggest hype-to-proof gap. Treat every one of these as promising-but-unproven for muscle growth, not as an established muscle drug.

The relatively strongest human data belongs to the indirect group, and even there it is not muscle-growth data. MK-677 has been studied in humans and reliably raises GH and IGF-1; a controlled trial in healthy older adults showed it increased fat-free mass over 12 months, though the change was largely water rather than functional muscle and it raised fasting glucose (Nass et al., Annals of Internal Medicine, 2008, retrieved 2026-06-19). Tesamorelin is the only molecule on this page with an FDA approval at all, but that approval is for reducing visceral fat in HIV-associated lipodystrophy, not for building muscle (FDA Egrifta prescribing information, retrieved 2026-06-19). The CJC-1295+ipamorelin stack and sermorelin reliably raise GH/IGF-1 in human pharmacology studies, but neither has a healthy-adult muscle-growth trial.

For the direct anabolics, the evidence is a tier lower and an order of magnitude less certain. IGF-1 LR3 acts directly on muscle IGF-1 receptors and there is strong biological rationale, but no human muscle-growth trial. MGF's satellite-cell and repair story comes from animal and cell work. And follistatin-344 - the most-hyped concept of all - rests on dramatic animal myostatin-inhibition results (the "double-muscled" models) with no controlled human muscle-growth trial; gene-therapy follistatin work exists in other indications, but that is not the research-grade peptide people inject. The chart below makes this concrete in the way that matters most for safety: it shows the glucose cost that the two highest-monitoring compounds (MK-677 and IGF-1 LR3) carry.

To make the gap concrete, the table below sorts every candidate by its highest muscle-relevant evidence tier with a year-anchored signal, so the human-trialed GH secretagogues stand apart from the animal-only direct anabolics at a glance.

The pattern is stark: the compounds with any human data are the indirect GH secretagogues, and even their human data is about GH, IGF-1, and body composition - not a clean muscle-growth outcome - while the direct anabolics that sound most powerful are animal-grade for muscle. That is the honest reason this page separates "what the community uses" from "what is proven."

The glucose caveat: why MK-677 and IGF-1 LR3 need bloodwork

Two of the three most-used compounds here carry a specific, well-documented metabolic cost: MK-677 raises fasting glucose and reduces insulin sensitivity, and direct IGF-1 LR3 can cause both hyperglycemia over time and acute hypoglycemia, so fasting-glucose and IGF-1 monitoring is not optional for either - it is the price of using them at all. This is the safety detail most "best peptides" lists skip, and it is exactly where first-party bloodwork data earns its keep.

The mechanism is straightforward. Higher GH and IGF-1 both push back against insulin, so a compound that chronically raises them tends to nudge fasting glucose upward and blunt insulin sensitivity. In MK-677's human trial, the fat-free-mass gain came alongside exactly this glucose drift (Nass et al., Annals of Internal Medicine, 2008, retrieved 2026-06-19). IGF-1 LR3 adds a second, more acute problem: because it acts directly on IGF-1 receptors that overlap with insulin signaling, it can drop blood sugar sharply around dosing, which is the source of the transient-low pattern in the chart above.

[ORIGINAL DATA] In our observed app bloodwork, the contrast is consistent and quietly important: MK-677 users tend to show a steady upward drift in fasting glucose into the upper-normal "watch" zone over about 12 weeks, while IGF-1 LR3 users sit a little lower on average but swing more day to day, including transient lows. This is observed data, not a controlled trial, and individual responses vary widely. But it converts an abstract warning into a concrete monitoring plan: if you use either compound, baseline and periodic fasting glucose, plus an IGF-1 level, are the minimum, and anyone with prediabetes, diabetes, or a family history of it should treat that as a strong reason to avoid them or stay under close clinical supervision.

Citation capsule. MK-677 and IGF-1 LR3 both warrant blood-glucose monitoring. In a 2008 controlled human trial, MK-677 increased fat-free mass (largely water) but also raised fasting glucose and reduced insulin sensitivity (Nass et al., Annals of Internal Medicine, 2008). Direct IGF-1 LR3 can cause both upward glucose drift and acute hypoglycemia around dosing because it acts on insulin-overlapping receptors. Baseline and periodic fasting glucose plus IGF-1 monitoring is the minimum for either; people with diabetes or prediabetes should avoid them or stay under close clinical supervision.

Recovery and sleep as a muscle-growth input

Muscle is built during recovery, not during training, so the GH-axis peptides' most reliable real-world contribution may be better sleep and recovery rather than direct hypertrophy - and our observed wearable data backs this, with users on GH secretagogues reporting modest gains in deep sleep and next-day recovery readiness. It is a quieter benefit than the marketing promises, but it is also the most defensible one.

The GH secretagogues, especially MK-677 and the CJC/ipa stack, are widely reported to deepen sleep, which makes biological sense: GH is released in pulses during deep slow-wave sleep, and nudging that system can reinforce it. Since deep sleep is when much of the day's recovery and tissue repair happens, better sleep is a legitimate, if indirect, muscle-growth lever - arguably more reliable than chasing a direct anabolic signal that has no human muscle trial behind it.

[PERSONAL EXPERIENCE] In our community's wearable data, the pattern we see most consistently is not a dramatic strength jump but a modest improvement in recovery metrics: users logging Apple Watch and similar data on GH secretagogues tend to report small upticks in deep-sleep minutes and next-day recovery or readiness scores, alongside the well-known appetite and water-retention effects. These are self-reported, uncontrolled observations, not a trial, and they are easy to over-read. But they reframe the realistic goal usefully: if the most reproducible effect is better sleep and recovery, then the rational pick weights tolerability and sustainability, not the most aggressive mechanism. For grounded before-and-after context and how to read transformation claims, see peptides before and after.

Our take: The most useful reframe on this whole page is that muscle is built in recovery, not in the vial. The GH-axis peptides' most reliable real-world contribution is often deeper sleep and faster recovery, which is a slower, less dramatic story than "removes the myostatin brake" - but it is the one our wearable data actually supports, and it is the one that compounds safely over months.

Each candidate, briefly (with where to go deeper)

Here is each candidate in two-to-four sentences - enough to place it, with a link up to its full guide for the science and dosing. This page owns the "which one, and why" decision for muscle growth; the mechanism, dosing, and side-effect depth live on each compound's hub.

CJC-1295 + Ipamorelin (the canonical stack)

The community's most-used muscle-growth option: a long-acting GHRH analog paired with a selective GH-releasing peptide that together raise your own pulsatile GH with minimal cortisol or prolactin spillover. It is indirect, research-grade, has no healthy-adult muscle trial, and is WADA-banned - but it is the genre's beginner-safe starter. Full mechanism and the two components: CJC-1295 complete guide and ipamorelin complete guide, with dosing on the CJC-1295 + ipamorelin dosage calculator.

MK-677 (Ibutamoren)

An oral ghrelin-receptor agonist that raises GH and IGF-1 - the convenient "no needles" GH-axis pick and the most human-studied secretagogue here. A 2008 trial raised fat-free mass (largely water) in older adults, but also raised fasting glucose, so monitoring is warranted; it is not FDA-approved and is WADA-banned. Full guide: MK-677 complete guide.

IGF-1 LR3

A long-acting IGF-1 analog that acts directly on muscle IGF-1 signaling - the experienced cohort's choice for the strongest direct signal. It has no human muscle trial, carries the most safety uncertainty here (hypoglycemia, growth-signaling concerns), needs glucose monitoring, and is research-grade and WADA-banned. Full guide: IGF-1 LR3 complete guide.

Sermorelin

A short-acting GHRH analog that nudges the pituitary to release its own GH - a gentle, well-known GH-axis on-ramp with a clinical history in GH evaluation. It is milder than the CJC/ipa stack, has no healthy-adult muscle trial, and is WADA-banned. Full guide: sermorelin complete guide.

Tesamorelin

The most rigorously trialed GHRH analog and the only molecule here with an FDA approval - but that approval is for reducing HIV-associated visceral fat, not for building muscle. People track it for the best-evidenced GH-axis pharmacology; for muscle it is off-label, can affect glucose, and is WADA-banned. Full guide: tesamorelin complete guide.

MGF

Mechano-growth factor, a splice variant of IGF-1 the body makes locally after mechanical loading, studied for activating muscle satellite cells and local repair. It is a direct anabolic with animal/preclinical data only, very short-acting, research-grade, and WADA-banned. Full guide: MGF complete guide.

Follistatin-344

A myostatin-pathway inhibitor: rather than pushing growth, it releases a natural brake on muscle, the mechanism behind "double-muscled" animal models. It is the most-hyped direct concept with the biggest hype-to-proof gap - animal data only, no human muscle trial, research-grade, WADA-banned. Full guide: follistatin-344 complete guide.

Hexarelin

A potent GH-releasing peptide tracked for strong acute GH pulses - an older, more aggressive GHRP than ipamorelin. It raises cortisol and prolactin and is prone to desensitization with continuous use, has no human muscle trial, and is research-grade and WADA-banned. Full guide: hexarelin complete guide.

BPC-157 (recovery support, not a muscle-builder)

Not a muscle-builder, but tracked alongside the others as a recovery adjunct - a "body protection compound" used on animal soft-tissue-healing data to protect tendons and joints under heavy loading and stay trainable. It builds no muscle directly, rests on animal data, was removed from the FDA interim 503A bulk-compounding list in April 2026 without approval, and its WADA status is uncertain. Full guide: BPC-157 complete guide, with the BPC+TB repair stack on best peptides for recovery.

The "other" tail: IGF-1 DES, GHRP-2, GHRP-6

A long tail of less-tracked compounds. IGF-1 DES is a fast, locally-acting IGF variant; GHRP-2 and GHRP-6 are older GH-releasing peptides (GHRP-6 drives strong hunger, GHRP-2 raises prolactin and cortisol), largely superseded by ipamorelin for cleaner GH release. These do not yet have dedicated hubs, so treat this as an orientation note: they are research-grade, have no human muscle trials, and are WADA-banned, and most users gravitate to the cleaner mainstream options above. TB-500 also shows up here as a recovery partner rather than a muscle-builder.

Where the muscle-growth decision ends and another cluster begins

A lot of "muscle peptide" content actually answers a different question - full multi-compound stacking, contest prep, or peptides-versus-steroids - so this page deliberately stays on the muscle-growth decision layer for the general optimizer and links out for the rest. Knowing the boundary keeps you from over-stacking, from chasing competitive-bodybuilding protocols you do not need, and from treating a sport-legality question as a muscle question.

Three near-neighbors get a forward link rather than a deep dive here. Full multi-compound stacks, bulk and cut phasing, contest prep, and the peptides-versus-steroids/SARMs comparison belong to best peptides for bodybuilding, which is the home for competitive culture and aggressive stacking - this page keeps stacking to the one canonical CJC+ipa combination and pushes the rest there on purpose. Athletic performance, strength, and endurance as primary goals belong to best peptides for endurance and the performance cluster; we link rather than re-cover them. And recovery and injury repair as the primary goal - the BPC+TB "Wolverine" stack and acute soft-tissue work - sit on best peptides for recovery. If your goal is lean-mass and hypertrophy for general optimization, you are in the right place.

What the community uses is not what is proven best

Treat the usage ranking as a popularity signal shaped by tradition, convenience, and marketing - not as evidence of what works best or safest. The clearest proof is follistatin-344: it sits in the usage tail on the strength of a thrilling animal-myostatin story, with no human muscle trial behind it, while the better-evidenced GH secretagogues do the quiet, unglamorous work.

Three honest framings sit on top of every number on this page. First, no peptide here is FDA-approved for muscle growth in healthy adults - tesamorelin's approval is for HIV-associated visceral fat, and everything else is investigational or research-grade; the indirect GH secretagogues at least have human GH/IGF-1 data, while the direct anabolics rest on animal work. Second, the direct anabolics carry the most risk for the least proof - IGF-1 LR3, MGF, and especially follistatin-344 sound more powerful than the GH-axis options precisely because they act more aggressively, but that same aggressiveness is the safety concern, and the human muscle evidence is not there. Third, research-grade vials carry quality risk - unknown potency, purity, and sterility - that no usage statistic captures, and all of these compounds are banned in tested sport under the WADA prohibited list, so any competitive athlete should treat this entire page as off-limits. Before sourcing anything, see how to vet peptide quality and are peptides legal.

Our take: The most useful way to read this page is as two layers. The usage chart tells you what real people are doing; the mechanism and evidence columns tell you what the data supports. They mostly agree here - the community sensibly leans indirect and beginner-safe - but the tail tells the cautionary story: the most exciting-sounding direct anabolics are the least proven and the most monitored. When mechanism hype and human evidence diverge, weight the evidence.

What muscle growth is realistic, and how fast?

Expect a slow, modest contribution rather than a transformation: the GH-axis peptides mostly support recovery, sleep, and body composition over months, the direct anabolics have no human muscle-growth timeline at all, and the early "gains" people report are often water and appetite rather than functional muscle. The dramatic before-and-afters are not the realistic baseline.

A few grounding facts make this usable. In MK-677's human trial, the fat-free-mass increase was real but largely water, not pure contractile muscle, and it built over many months (Nass et al., Annals of Internal Medicine, 2008, retrieved 2026-06-19). The CJC/ipa stack and sermorelin raise GH/IGF-1 and may improve recovery and sleep, but they are not magic muscle switches, and their muscle-growth timeline in healthy adults is simply unstudied. For the direct anabolics, any timeline you read is an extrapolation: there is no human muscle trial to anchor a "results in X weeks" claim for IGF-1 LR3, MGF, or follistatin-344, so the fast-gain stories should be treated as anecdotes, water, or training-plus-nutrition effects that would have happened anyway.

The practical read for choosing: none of these replaces the actual drivers of hypertrophy, which are progressive-overload training, adequate protein, and sleep. The realistic role of a peptide here is, at best, a modest assist on the margins - better recovery, deeper sleep, a small body-composition nudge - layered on top of the training and nutrition that do the real work. Anyone framing a peptide as the primary cause of muscle growth has the order backwards, and the people happiest with these protocols in our community notes are the ones who treated the peptide as the smallest variable, not the biggest. For grounded before-and-after context, see peptides before and after.

Our take: The most common mistake is anchoring to a follistatin "double-muscled" fantasy and expecting a peptide to do what training and food do. None of these is a shortcut around progressive overload, protein, and sleep. The realistic win is a modest recovery-and-body-composition assist on top of a serious training program - and choosing the option you can run safely and consistently beats chasing the most aggressive mechanism.

Who should be cautious, and who should not use these

Muscle-growth peptides are not for everyone, and the research-grade ones are not for anyone outside a clinician's oversight - and they are entirely off-limits for any athlete subject to drug testing. The GH secretagogues carry real metabolic and contraindication concerns, and the direct anabolics add unknown-risk growth signaling on top.

A few hard lines worth stating. Anyone with diabetes or prediabetes should be especially cautious with MK-677 and IGF-1 LR3, both of which can worsen glucose control, and should not use them without close clinical monitoring. Because GH and IGF-1 are growth signals, these compounds are a particular caution for anyone with a personal or family history of cancer, and tissue-growth-signaling agents should be avoided where any active or prior malignancy is a concern. None of these should be used in pregnancy or breastfeeding. Tesamorelin is approved only for a specific HIV-related indication, not for muscle, and using it off-label still carries its glucose and other label warnings. And critically, every compound on this page is on the WADA prohibited list, so any competitive or tested athlete who uses them risks sanctions and should treat this entire category as prohibited. For everyone else, the research-grade reality - no validated safe-use protocol, unregulated supply, and no human muscle-growth trial - means these belong under a clinician's oversight, not in a self-directed cycle. None of this page is a substitute for that conversation.

Frequently Asked Questions

The bottom line

If you came here for a single "best peptide for muscle growth," the honest answer is layered. The community's most-used option is the CJC-1295+ipamorelin GH-axis stack by a wide margin, and that is a defensible default: it is indirect, gentle, beginner-appropriate, and works with your own growth-hormone system - even though, like everything here, it has no human muscle-growth trial and is banned in tested sport. The single distinction that should drive your choice is indirect versus direct. The GH-axis secretagogues raise your own GH and IGF-1 with more human data and less risk; the direct anabolics - IGF-1 LR3, MGF, and especially follistatin-344 - offer a stronger, more aggressive signal that rests on animal data and carries the most safety uncertainty, including the glucose caveat that makes monitoring mandatory for MK-677 and IGF-1 LR3.

So choose by your experience and your tolerance for unproven risk. New to this, and you want the beginner-safe GH-axis on-ramp, the CJC+ipa stack (or milder sermorelin) is what the community uses. You want oral convenience and will monitor glucose, MK-677. You are experienced and accept the most direct signal and the most monitoring, IGF-1 LR3 - eyes open that there is no human muscle trial. And remember the reframe that matters most: muscle is built in recovery, not in the vial, so the realistic win is a modest recovery-and-sleep assist on top of serious training and nutrition. The selector at the top narrows the field to your constraints, but the final call belongs with a clinician who knows your health history. From here, the natural next reads are best peptides for bodybuilding for full stacking, best peptides for recovery, and how to vet peptide quality.

Sources

• Nass R, Pezzoli SS, Oliveri MC, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults (MK-677/ibutamoren): a randomized trial." Annals of Internal Medicine, 2008. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/19017583/
• U.S. Food & Drug Administration. "Egrifta (tesamorelin for injection) - Prescribing Information" (approved for HIV-associated lipodystrophy / visceral fat, not muscle growth). 2014. Retrieved 2026-06-19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022505s007lbl.pdf
• Sinha DK, Balasubramanian A, Tatem AJ, et al. "Beyond the androgen receptor: the role of growth hormone secretagogues (GHRH analogs and GHRPs) in body composition." Translational Andrology and Urology, 2020. Retrieved 2026-06-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
• Lee SJ, McPherron AC. "Regulation of myostatin activity and muscle growth (follistatin and myostatin inhibition, animal models)." Proceedings of the National Academy of Sciences, 2001. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/11459935/
• Goldspink G. "Mechano-growth factor (MGF), an IGF-1 splice variant, and its role in muscle repair and satellite-cell activation (preclinical)." Journal of Musculoskeletal and Neuronal Interactions, 2007. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/17675759/
• World Anti-Doping Agency. "The Prohibited List - S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics" (includes GH secretagogues, GHRH analogs/GHRPs, IGF-1 and related growth factors). 2026. Retrieved 2026-06-19. https://www.wada-ama.org/en/prohibited-list
• U.S. Food & Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act" (BPC-157 status, 2026 update). Retrieved 2026-06-19. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdc-act
• ProtocolPlus. "Community goal-usage data: muscle growth" (goals/muscle-growth.json). First-party app data, 2026. n ≈ 3,000 users pursuing muscle growth. Usage signal, not a clinical efficacy ranking.
• ProtocolPlus. "Observed bloodwork and wearable-recovery deltas" - fasting-glucose and IGF-1 movement on GH secretagogues vs IGF-1 LR3; deep-sleep and recovery-readiness deltas on GH secretagogues. Observed app data, 2026, not a clinical trial.